The following physicians have joined the MAPS Medical Advisory Board
- Cynthia Fields, MD, Assistant Professor of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine
Dr. Fields is a psychiatrist in Baltimore, Maryland and is affiliated with multiple hospitals in the area, including MedStar Good Samaritan Hospital and Johns Hopkins Hospital. She received her medical degree from the University of Connecticut and has been in practice for more than 20 years. Dr. Fields has expertise in treating anxiety disorders, bipolar disorder, depression, among other conditions – see all areas of expertise.
- Rebecca Rye, CRNP-PMH, Board-Certified Nurse Practitioner
Rebecca Rye CRNP-PMH is a psychiatric nurse practitioner in Johns Hopkins Hospital Geriatric and Neuropsychiatry Department . She has 35 years of experience in inpatient, emergency room and outpatient experience in psychiatry. Rebecca has practiced as a psychiatric nurse practitioner for the past 12 years in Geriatric Psychiatry Outpatient Clinic, Parkinson’s Neuropsychiatry Clinic and The Frontotemporal Dementia and Young Onset Dementia Clinic. She has also worked in the Geriatric Partial Hospitalization Program and the Psychogeriatric Outreach and Mobile Treatment Program (PATCH). In 2020 she was the recipient of the Johns Hopkins Hospital Miller Coulson Academy of Clinical Excellence Nurse Practitioner award. Rebecca is co-author on several papers related to geriatric mobile treatment. Her clinical interests include elderly patients with mental illness and dementia, working with families/care partners, and the management of non-motor symptoms in patients with Parkinson’s Disease.
- Gwenn Smith, Ph.D. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Director, Division of Geriatric Psychiatry and Neuropsychiatry, Co-Director, Center for Translational Molecular Imaging, Johns Hopkins Bayview
For over two decades, Dr. Smith’s research has focused on the development and application of positron emission tomography (PET) imaging methods to understand functional neuroanatomic and monoaminergic mechanisms associated with vulnerability to cognitive decline in late life, as well as to understand the mechanisms underlying the mood and cognitive responses to medication and brain stimulation treatment. In addition to the role of neuroimaging as a bridge between basic and clinical neuroscience, she appreciated early in her career that neuroimaging represents an unique opportunity to understand the earliest neurobiological changes that occur in cognitive and mood disorders in late life and to inform the development of more effective treatments. While the majority of this work has focused on late-life depression, mild cognitive impairment and Alzheimer’s and Parkinson’s disease, the methods developed have been applied to other neuropsychiatric disorders including schizophrenia and traumatic brain injury.